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TO THE EDITOR:
Lung transplantation is a complex procedure that 
requires extracorporeal mechanical cardiopulmonary 
support in many situations. Such support can be provided 
preoperatively, intraoperatively, or postoperatively, 
depending on the patient’s severity of illness and clinical 
status. This occurs in approximately 30-40% of lung 
transplants. The situations that most commonly require 
such support in the intraoperative period include pulmonary 
arterial hypertension (PAH), right ventricular dysfunction, 
and intolerance to single-lung ventilation.(1) The optimal 
strategy remains a matter of debate(2); however, the use 
of extracorporeal membrane oxygenation (ECMO) has 
been shown to provide numerous benefits over the use of 
cardiopulmonary bypass. This is because ECMO support 
resulted in lower rates of primary graft dysfunction (PGD), 
bleeding, and renal failure requiring dialysis, as well as 
a lower rate of tracheostomy, less intraoperative blood 
transfusion, shorter durations of mechanical ventilation, 
and shorter hospital stays.(3)
Between January of 2017 and December of 2018, 24 lung 
transplants were performed at the Porto Alegre Hospital 
de Clínicas, located in the city of Porto Alegre, Brazil. The 
clinical and laboratory data from those transplant recipients 
were statistically analyzed by using the chi-square and 
Mann-Whitney U tests and are shown in Table 1. Of the 
24 patients included in the analysis, 12 received ECMO for 
cardiopulmonary support, 11 (92%) of whom underwent 
bilateral lung transplantation, whereas 12 did not require 
ECMO, 7 (58%) of whom underwent unilateral lung 
transplantation. Suppurative lung diseases accounted 
for 50% of the cases of patients transplanted with ECMO 
support. In patients who did not require ECMO, a diagnosis 
of COPD was more prevalent. The first use of ECMO at 
our center was as a bridge to transplantation. Three of 
the patients in the ECMO group, given the impossibility of 
establishing single-lung ventilation, received venovenous 
(VV) ECMO only for ventilatory support. The remaining 
patients received venoarterial (VA) ECMO for ventilatory 
and hemodynamic support. Patients with significant PAH 
underwent peripheral cannulation under local anesthesia 
and sedation prior to induction of anesthesia. Patients 
without PAH or with mildly elevated pulmonary pressure 
underwent central arterial cannulation of the thoracic 
aorta and peripheral venous cannulation of the right 
femoral vein. At the end of the procedure, VA ECMO was 
continued in patients with PAH or was converted to VV 
ECMO if the patient was hemodynamically stable and 
did not have PAH. To that end, a single-lumen catheter 
previously positioned in the right internal jugular vein 
allowed placement of a guidewire and local cannulation. 
Thus, the aortic arterial cannula was disconnected and 
removed after reconnection with the jugular vein cannula. 
Decannulation from VV ECMO was performed in the ICU 
after extubation and confirmation of absence of PGD. 
There was no difference in hospital or ICU lengths of 
stay between patients who received ECMO and those 
who did not, although the former were more severely ill, 
as demonstrated by the need to use a greater volume of 
crystalloids, the greater need for transfusion, the longer 
operative times, and the higher percentage of bilateral 
transplants. The estimated 36-month survival was 66.7% 
among patients who received ECMO, compared with 
91.7% among those who did not. Although mortality 
was higher in the ECMO group, the difference was not 
statistically significant (p = 0.143).
The first reports of the use of ECMO date back to the 
1970s; however, they were limited to experimental 
strategies with unfavorable outcomes.(4) The use of 
ECMO in the pediatric population and in patients with 
ARDS(5) has resulted in technical progress and increased 
experience. Although the use of ECMO during lung 
transplantation was first described in 2001, it has only 
recently been introduced in Brazil.(6) VV ECMO provides 
ventilatory support by drawing deoxygenated blood from 
the venous system in order to oxygenate it and return 
it to the same system. In contrast, VA ECMO enables 
cardiopulmonary bypass by returning oxygenated blood 
to the arterial system.(7) Intraoperative ECMO, in addition 
to ensuring greater safety during cardiac manipulation, 
reduces the chance of reperfusion injury by allowing 
better control of blood flow after the pulmonary artery 
clamp is released, thereby preventing the first implanted 
graft from receiving the entire cardiac output during 
implantation of the second graft. In addition, intraoperative 
ECMO precludes the need for aggressive ventilation to 
maintain gas exchange and allows continued support 
in the postoperative period.(2) In patients with PAH or 
considerable hemodynamic instability, it is essential to 
maintain VA support in the postoperative period, since 
cardiac output has to be reduced to enable remodeling 
of the right ventricle, which is chronically hypertrophic. (8) 
In other patients, there is no consensus on the type of 
or need for postoperative support. As for our team, in 
cases in which it is possible to discontinue VA support at 
the end of the surgery, we prefer to avoid decannulation 
and carry out conversion from VA to VV support, which is 
continued in the postoperative period. Thus, mechanical 
ventilation at protective settings is delivered until early 
extubation is achieved and spontaneous ventilation begins. 
The use of VV ECMO for the treatment of severe PGD 
is well established, increasing survival and minimizing 
the deleterious effects of mechanical ventilation. There 
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is also evidence that the institution of ECMO within 
2 hours of the diagnosis of grade 3 PGD results in 
increased survival, whereas delayed institution of 
ECMO is associated with very high mortality.(9) Other 
studies have shown that cases requiring ECMO for the 
treatment of PGD have a significantly reduced rate of 
long-term graft survival, as compared with cases not 
requiring such management.(10) Thus, institution of VA 
ECMO in the intraoperative period helps hemodynamic 
stability and provides protection for the graft, whereas 
continued VV support in the postoperative period 
reduces the need for mechanical ventilation and provides 
preemptive treatment of possible reperfusion injury.
In our experience, we found that the use of ECMO 
to provide cardiopulmonary support in patients with 
suppurative lung disease with or without concomitant 
PAH resulted in good survival, although these patients 
were more severely ill than those who did not receive 
ECMO; however, hospital and ICU lengths of stay 
were similar in both groups of patients, making this 
strategy an important part of the therapeutic arsenal 
in the setting of lung transplantation.
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Table 1. Data from patients undergoing pulmonary transplantation between January of 2017 and December of 2018. 
Porto Alegre Hospital de Clínicas, Porto Alegre, Brazil.a
Data Groups p
ECMO No ECMO 
(n = 12) (n = 12)
Gender (M/F) 7 (58%)/5 (42%) 6 (50%)/6 (50%) 0.68





























PASP ≥ 35 mmHg 7 (58%) 2 (17%) 0.09
MPAP, mmHg 28 (17-79) 22 (13-32) 0.16
FEV1, % predicted 21% (16-70%) 23% (17-42%) 0.63
FVC, % predicted 37% (13-78%) 40% (33-56%) 0.16
Operative time, h 11 (8-17) 6 (3-11) < 0.001
Cold ischemia time of the first graft, min 432 (270-540) 400 (205-558) 0.45
Cold ischemia time of the second graft, min 632 (520-720) 635 (480-705) 0.82
Crystalloid, mL 6,500 (3,000-32,600) 2,800 (1,400-7,000) < 0.001
Need for blood transfusion 9 (75%) 1 (8%) 0.001
ICU length of stay, days 12 (5-103) 7 (2-16) 0.17
Hospital length of stay, days 27 (20-117) 29 (17-76) 0.84
90-day mortality 3 (25%) 1 (8%) 0.27
Mean estimated 36-month survival, months 27 35 0.143*
aValues expressed as n, n (%), or median (minimum-maximum). ECMO: extracorporeal membrane oxygenation; 
M/F: male/female; PAH: pulmonary arterial hypertension; PASP: pulmonary artery systolic pressure; and MPAP: 
mean pulmonary artery pressure. *Log-rank test comparing the Kaplan-Meier curves of the two groups.
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